Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Theodoros Foukakis

Showing results (111-120 of 128) with videos related to

Pageof 13
Sort By:
Annals of Surgical Oncology|March 12, 2026
ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 StudySherko Kuemmel, Peter A Fasching, Peter Schmid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 2022
Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 TrialAlexios Matikas, Hemming Johansson, Per Grybäck, et al.
The New England Journal of Medicine|February 27, 2020
Pembrolizumab for Early Triple-Negative Breast CancerPeter Schmid, Javier Cortes, Lajos Pusztai, et al.
NPJ Breast Cancer|August 22, 2020
Long-term anti-inflammatory diet in relation to improved breast cancer prognosis: a prospective cohort studyKang Wang, Jia-Zheng Sun, Qian-Xue Wu, et al.
JAMA|November 9, 2016
Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical TrialTheodoros Foukakis, Gunter von Minckwitz, Nils-Olof Bengtsson, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 22, 2015
First results of the preoperative accelerated partial breast irradiation (PAPBI) trialFemke van der Leij, Sophie C J Bosma, Marc J van de Vijver, et al.
The New England Journal of Medicine|September 16, 2024
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast CancerPeter Schmid, Javier Cortes, Rebecca Dent, et al.
Breast (Edinburgh, Scotland)|June 29, 2026
Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: A systematic literature review of real-world evidenceRodrigo Sanchez-Bayona, Carey Anders, Rupert Bartsch, et al.
JAMA Oncology|June 24, 2021
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical TrialThomas Hatschek, Theodoros Foukakis, Judith Bjöhle, et al.
Nature Communications|April 8, 2026
Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trialAlexios Matikas, Evangelos Tzoras, Michail Sarafidis, et al.
Pageof 13

Showing results (111-120 of 128) with videos related to

Sort By:
Pageof 13
Annals of Surgical Oncology|March 12, 2026
ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 StudySherko Kuemmel, Peter A Fasching, Peter Schmid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 2022
Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 TrialAlexios Matikas, Hemming Johansson, Per Grybäck, et al.
The New England Journal of Medicine|February 27, 2020
Pembrolizumab for Early Triple-Negative Breast CancerPeter Schmid, Javier Cortes, Lajos Pusztai, et al.
NPJ Breast Cancer|August 22, 2020
Long-term anti-inflammatory diet in relation to improved breast cancer prognosis: a prospective cohort studyKang Wang, Jia-Zheng Sun, Qian-Xue Wu, et al.
JAMA|November 9, 2016
Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical TrialTheodoros Foukakis, Gunter von Minckwitz, Nils-Olof Bengtsson, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 22, 2015
First results of the preoperative accelerated partial breast irradiation (PAPBI) trialFemke van der Leij, Sophie C J Bosma, Marc J van de Vijver, et al.
The New England Journal of Medicine|September 16, 2024
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast CancerPeter Schmid, Javier Cortes, Rebecca Dent, et al.
Breast (Edinburgh, Scotland)|June 29, 2026
Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: A systematic literature review of real-world evidenceRodrigo Sanchez-Bayona, Carey Anders, Rupert Bartsch, et al.
JAMA Oncology|June 24, 2021
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical TrialThomas Hatschek, Theodoros Foukakis, Judith Bjöhle, et al.
Nature Communications|April 8, 2026
Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trialAlexios Matikas, Evangelos Tzoras, Michail Sarafidis, et al.
Pageof 13